BMRN - Massive Insider Trade At Biomarin Pharmaceutical | Benzinga
HENRY FUCHS, President at Biomarin Pharmaceutical (NASDAQ:BMRN), reported an insider sell on March 7, according to a new SEC filing.
What Happened: FUCHS's decision to sell 35,341 shares of Biomarin Pharmaceutical was revealed in a Form 4 filing with the U.S. Securities and Exchange Commission on Thursday. The total value of the sale is $3,010,395.
In the Friday's morning session, Biomarin Pharmaceutical's shares are currently trading at $86.05, experiencing a up of 0.19%.
Delving into Biomarin Pharmaceutical's Background
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Biomarin Pharmaceutical: Delving into Financials
Revenue Growth: Biomarin Pharmaceutical's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 20.22%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved ...